未登录Utilization of extended-interval, fixed-dosing of durvalumab, every 4 weeks, in US patients with unresectable stage III NSCLC following concurrent chemoradiation
Haque, Reina; Mcgary, Eric; Yang, Mike Z.; Liu, Raymond; Suga, J. Marie; Chen, Liehong; Zhu, Zheng; Simmons, Daniel J.; Hsieh, Kristin; Cotarla, Ion; Sakoda, Lori C.
分享
收藏
分享
收藏
分享
收藏
分享
收藏